Baloxavir marboxil significantly reduced the likelihood of influenza transmission from the infected patient to the household contacts. Treatment with baloxavir marboxil significantly reduced the risk ...

It is not inevitable that H5N1 will develop into a pandemic -- if we act now. Unfortunately, instead of urgent action, we ...

Results from a late-stage study on RHHBY's Xofluza show that the drug reduces the transmission of influenza from an infected ...

Roche announces phase III CENTERSTONE study of Xofluza significantly reduces the transmission of influenza viruses: Basel Friday, September 20, 2024, 09:00 Hrs [IST] Roche announc ...

SOUTH SAN FRANCISCO, Calif., September 19, 2024--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today positive topline results of the Phase III CENTERSTONE study of ...

Roche's phase 3 CENTERSTONE study shows Xofluza (baloxavir marboxil) significantly reduces influenza transmission in ...

Roche today released positive top-line results of the Phase III CENTERSTONE study of Xofluza (baloxavir marboxil), an ...

According to the company, the results are the first time an antiviral drug has reduced transmission of a respiratory virus in ...

Roche (RHHBF) unit Genentech said Xofluza antiviral reached the main goal in a global Phase 3 trial, reducting the ...

Roche has achieved a research success with its flu drug Xofluza: As the latest data from a study show, Xofluza has reduced the transmission of influenza from an infected person to household members.

Roche has achieved a research success with its influenza drug Xofluza. As the latest data from the pivotal Centerstone study show, Xofluza has reduced the transmission of influenza from an infected ...

Xofluza (baloxavir marboxil), an antiviral medication, achieved its primary endpoint in the phase III CENTERSTONE ...